Search results
Showing 1 to 4 of 4 results for lebrikizumab
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)
Evidence-based recommendations on lebrikizumab (Ebglyss) for treating moderate to severe atopic dermatitis in people 12 years and over.
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)
Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.
Lebrikizumab for treating atopic dermatitis in children [TSID12133]
Topic prioritisation
Lebrikizumab for treating atopic dermatitis in children [TSID 12133_TSID 12135]
Topic prioritisation